Victoria Lm Herrera1, Aaron H Colby2, Glaiza Al Tan1, Ann M Moran1, Michael J O'Brien3, Yolonda L Colson4, Nelson Ruiz-Opazo1, Mark W Grinstaff1,2. 1. Department of Medicine & Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, MA 02118, USA. 2. Departments of Biomedical Engineering & Chemistry, Boston University, Boston, MA 02215, USA. 3. Department of Pathology & Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA. 4. Division of Thoracic Surgery, Department of Surgery, Brigham & Women's Hospital, Boston, MA 02115, USA.
Abstract
AIM: To evaluate the tumor localization and efficacy pH-responsive expansile nanoparticles (eNPs) as a drug delivery system for pancreatic peritoneal carcinomatosis (PPC) modeled in nude rats. METHODS & MATERIALS: A Panc-1-cancer stem cell xeno1graft model of PPC was validated in vitro and in vivo. Tumor localization was tracked via in situ imaging of fluorescent eNPs. Survival of animals treated with paclitaxel-loaded eNPs (PTX-eNPs) was evaluated in vivo. RESULTS: The Panc-1-cancer stem cell xenograft model recapitulates significant features of PPC. Rhodamine-labeled eNPs demonstrate tumor-specific, dose- and time-dependent localization to macro- and microscopic tumors following intraperitoneal injection. PTX-eNPs are as effective as free PTX in treating established PPC; but, PTX-eNPs result in fewer side effects. CONCLUSION: eNPs are a promising tool for the detection and treatment of PPC.
AIM: To evaluate the tumor localization and efficacy pH-responsive expansile nanoparticles (eNPs) as a drug delivery system for pancreatic peritoneal carcinomatosis (PPC) modeled in nude rats. METHODS & MATERIALS: A Panc-1-cancer stem cell xeno1graft model of PPC was validated in vitro and in vivo. Tumor localization was tracked via in situ imaging of fluorescent eNPs. Survival of animals treated with paclitaxel-loaded eNPs (PTX-eNPs) was evaluated in vivo. RESULTS: The Panc-1-cancer stem cell xenograft model recapitulates significant features of PPC. Rhodamine-labeled eNPs demonstrate tumor-specific, dose- and time-dependent localization to macro- and microscopic tumors following intraperitoneal injection. PTX-eNPs are as effective as free PTX in treating established PPC; but, PTX-eNPs result in fewer side effects. CONCLUSION: eNPs are a promising tool for the detection and treatment of PPC.
Authors: Hongyi Lei; Sophie C Hofferberth; Rong Liu; Aaron Colby; Kristie M Tevis; Paul Catalano; Mark W Grinstaff; Yolonda L Colson Journal: J Thorac Cardiovasc Surg Date: 2015-02-14 Impact factor: 5.209
Authors: I Vogel; U Krüger; J Marxsen; E Soeth; H Kalthoff; D Henne-Bruns; B Kremer; H Juhl Journal: Clin Cancer Res Date: 1999-03 Impact factor: 12.531
Authors: Aaron P Griset; Joseph Walpole; Rong Liu; Ann Gaffey; Yolonda L Colson; Mark W Grinstaff Journal: J Am Chem Soc Date: 2009-02-25 Impact factor: 15.419
Authors: Irene Thomassen; Valery E P P Lemmens; Simon W Nienhuijs; Misha D Luyer; Yvonne L Klaver; Ignace H J T de Hingh Journal: Pancreas Date: 2013-01 Impact factor: 3.327
Authors: Victoria L Herrera; Julius L Decano; Glaiza A Tan; Ann M Moran; Khristine A Pasion; Yuichi Matsubara; Nelson Ruiz-Opazo Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240
Authors: Victoria Lm Herrera; Aaron H Colby; Nelson Ruiz-Opazo; David G Coleman; Mark W Grinstaff Journal: Nanomedicine (Lond) Date: 2018-09-11 Impact factor: 5.307
Authors: Derek Hargrove; Brian Liang; Raana Kashfi-Sadabad; Gaurav N Joshi; Laura Gonzalez-Fajardo; Sterling Glass; Michael Jay; Andrew Salner; Xiuling Lu Journal: J Control Release Date: 2020-11-07 Impact factor: 9.776
Authors: Aaron H Colby; Samantha M Berry; Ann M Moran; Kristine Amber Pasion; Rong Liu; Yolonda L Colson; Nelson Ruiz-Opazo; Mark W Grinstaff; Victoria L M Herrera Journal: ACS Nano Date: 2017-02-01 Impact factor: 15.881
Authors: Aaron H Colby; Nicholas H Oberlies; Cedric J Pearce; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2017-02-09
Authors: Rong Liu; Aaron H Colby; Denis Gilmore; Morgan Schulz; Jialiu Zeng; Robert F Padera; Orian Shirihai; Mark W Grinstaff; Yolonda L Colson Journal: Biomaterials Date: 2016-06-23 Impact factor: 12.479
Authors: Christopher Gromisch; Motaz Qadan; Mariana Albuquerque Machado; Kebin Liu; Yolonda Colson; Mark W Grinstaff Journal: Cancer Res Date: 2020-03-27 Impact factor: 12.701
Authors: Amrita Salvi; Chiraz Soumia M Amrine; Julia R Austin; KiAundra Kilpatrick; Angela Russo; Daniel Lantvit; Esther Calderon-Gierszal; Zachary Mattes; Cedric J Pearce; Mark W Grinstaff; Aaron H Colby; Nicholas H Oberlies; Joanna E Burdette Journal: Mol Cancer Ther Date: 2020-01 Impact factor: 6.261
Authors: Maciej Nowacki; Margarita Peterson; Tomasz Kloskowski; Eleanor McCabe; Delia Cortes Guiral; Karol Polom; Katarzyna Pietkun; Barbara Zegarska; Marta Pokrywczynska; Tomasz Drewa; Franco Roviello; Edward A Medina; Samy L Habib; Wojciech Zegarski Journal: Oncotarget Date: 2017-08-31